Introduction Cancer remains Australia’s leading cause of disease burden. 1 As the largest private provider of cancer care in Australia, GenesisCare has both a responsibility and the privilege to contribute to improved outcomes for patients. Research and clinical trials are embedded across the majority of its 52 clinics nationwide, positioning GenesisCare as a key contributor to treatment innovation and the acceleration of cancer outcomes. Biomarker-driven oncology now underpins modern cancer care. Almost half of all oncology clinical trials incorporate biomarkers, reflecting a shift from traditional organ-based treatment approaches toward molecularly targeted therapies. Increasingly, trials assess multiple biomarkers simultaneously - including pan- tumour markers - allowing treatment decisions to be guided by tumour biology rather than anatomical site alone. This evolution is reflected at GenesisCare, where more than 80% of coordinated oncology clinical trials now involve molecularly targeted therapies , aligning with the organisation’s patient-centred approach to care. Advances in precision radiation therapy are also expanding the role of radiation oncology

Ongoing focus on biomarker-driven trials, data integration, workforce capability, and scalable research infrastructure will be critical to maintaining Australia’s global standing in cancer innovation while delivering meaningful benefits for patients. Across the GenesisCare network in 2025, there were 163 active unique research projects , increasing to 217 nationally when multi-site studies are included. These encompassed interventional trials and observational research across medical oncology, haematology, radiation oncology, and theranostics. In parallel, GenesisCare contributed to more than 80 external research initiatives and clinical quality registries and produced 62 peer-reviewed publications . Collectively, these activities demonstrate a balanced and strategic investment in therapeutic innovation, outcomes research, and real-world evidence generation. Through this work, GenesisCare clinicians and research teams continue to achieve national and international recognition for excellence in clinical research, innovation, and academic leadership - reinforcing the organisation’s role in delivering evidence-based, patient-centred cancer care.

beyond malignant disease. In selected benign conditions, high-precision, low-dose radiation can offer durable symptom control with minimal risk. 4-9 Contemporary applications include benign brain tumours, functional disorders, vascular abnormalities, and emerging indications in degenerative and inflammatory musculoskeletal conditions. This broadened scope reflects the evolution of radiation oncology from a tumour-focused discipline to one that applies precision radiation science to support patient-centred outcomes across a wider spectrum of disease. GenesisCare continues to leverage advanced technologies such as stereotactic radiosurgery and image-guided radiation therapy to improve tumour control while minimising toxicity. 2,3 These technologies are increasingly integrated with systemic therapies and precision-led clinical trials. Sustained investment in precision oncology aligns with both GenesisCare’s strategic priorities and the objectives of the Australian Cancer Plan, developed by Cancer Australia, which emphasises personalised care, equity of access, and improved outcomes.

Dr Marcus Dreosti BSc, Hons LLB, MBBS (Hons) FRANZCR Chief Medical Officer Radiation Oncologist

Sonya McColl BHlthSc (Nursing), RN, AdvDip (Management) Head of Research GenesisCare Australia

4

5

Made with FlippingBook Annual report maker